Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Esperion (NASDAQ: ESPR) provided preliminary full‑year 2025 results and a business update on Jan 11, 2026, and outlined its long‑term Vision 2040 growth strategy. Key preliminary figures: U.S. net product sales $156–$160M (+35%–38% vs 2024), total revenue $400–$408M (+20%–23% vs 2024; ~55%–59% excl. one‑time milestones), and cash & cash equivalents ≈ $168M at year‑end 2025. Q4 retail prescription equivalents rose 34% Y/Y and 11.3% Q/Q. Company expects 2026 operating expenses $210–$245M and announced R&D and global commercial expansion, including IND‑enabling work for ESP‑2001 (PSC) and plans for oral triple combination lipid therapies targeted for commercialization in 2027.

Positive

• U.S. net product sales of $156–$160M (+35%–38% YoY)
• Total preliminary revenue of $400–$408M (+20%–23% YoY)
• Q4 retail prescription equivalents up 34% Y/Y and 11.3% Q/Q
• Patent settlements restricting generic entry by four ANDA filers until April 2040
• Received a $90M payment related to Japan regulatory approval
• Completed a $75M capital raise in 2025

Negative

• Year‑end cash of ≈ $168M vs 2026 operating expense guidance of $210–$245M, indicating limited near‑term runway without additional funding
• Total preliminary revenue includes one‑time milestone payments, creating volatility in underlying recurring revenues

News Market Reaction

-8.51%

7 alerts

-8.51% News Effect

-$80M Valuation Impact

$857M Market Cap

1.3x Rel. Volume

On the day this news was published, ESPR declined 8.51%, reflecting a notable negative market reaction. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $80M from the company's valuation, bringing the market cap to $857M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

2025 U.S. net product sales: $156–$160M 2025 total revenue: $400–$408M Year-end 2025 cash: $168M +5 more

8 metrics

2025 U.S. net product sales $156–$160M Preliminary full-year 2025 U.S. net product sales; 35%–38% growth vs 2024

2025 total revenue $400–$408M Preliminary full-year 2025 revenue; 20%–23% growth vs 2024

Year-end 2025 cash $168M Cash and cash equivalents at year-end 2025 (preliminary)

Q4 Rx growth Y/Y 34% Q4 2025 retail prescription equivalents year-over-year growth

Q4 Rx growth Q/Q 11.3% Q4 2025 retail prescription equivalents sequential quarter-over-quarter growth

2026 operating expenses $210–$245M Expected full-year 2026 operating expenses, incl. $15M stock comp

2025 capital raise $75.0M Capital raise completed in 2025 to support expansion and pipeline

Otsuka payment $90M Total payment from Otsuka tied to Japan approval and pricing

Market Reality Check

Price: $3.17 Vol: Volume 4,736,422 vs 20-da...

normal vol

$3.17 Last Close

Volume Volume 4,736,422 vs 20-day average 5,336,752, indicating slightly below-normal trading activity before this update. normal

Technical Shares at $3.88 are trading above the 200-day MA of $2.11 and sit 7.07% below the 52-week high of $4.175.

Peers on Argus

Pre-news, ESPR slipped 0.77% while close peers were mixed: AQST -3.1%, SIGA -2.5...

1 Up 1 Down

Pre-news, ESPR slipped 0.77% while close peers were mixed: AQST -3.1%, SIGA -2.51%, EOLS +0.18%, AKBA +1.33%, ORGO +0.72%. Momentum scanner only flagged CGC -4.06% and EOLS +6.73%, reinforcing a stock-specific rather than sector-wide pattern.

Historical Context

5 past events · Latest: Jan 05 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 05	Conference participation	Neutral	+2.7%	J.P. Morgan conference appearance and webcast access details.
Dec 19	Guideline recognition	Positive	+3.4%	ACC statement recommending bempedoic acid for PAD with diabetes.
Dec 09	Insider inducement grants	Neutral	+1.1%	Equity awards and options for new Chief Commercial Officer.
Nov 21	Japan launch milestone	Positive	+4.4%	Otsuka launch of NEXLETOL in Japan and $90M payment.
Nov 19	Conference participation	Neutral	-1.4%	Piper Sandler healthcare conference presentation announcement.

Pattern Detected

Over the last five news events, ESPR has typically seen modestly positive price reactions, especially around clinical/regulatory and commercial expansion updates, with only one notable negative divergence.

Recent Company History

Across the last five news items since Nov 19, 2025, Esperion has highlighted conference participation, new guideline recommendations, insider-related equity grants, and major commercial milestones such as the Japan launch with Otsuka and broader international expansion. Price reactions were mostly positive following these announcements, suggesting investors have rewarded regulatory and commercial progress. Today’s broad business update and Vision 2040 strategy build directly on that trajectory of expanding global reach, ACLY-focused pipeline development, and cardiovascular franchise strengthening.

Market Pulse Summary

The stock moved -8.5% in the session following this news. A negative reaction despite the upbeat upd...

Analysis

The stock moved -8.5% in the session following this news. A negative reaction despite the upbeat update would contrast with recent patterns where regulatory and commercial news often preceded gains. The release highlights strong preliminary 2025 revenue of $400–$408M and expanding global partnerships, yet also introduces higher 2026 operating expense guidance of $210–$245M and continued pipeline investment. Weakness could reflect concern about execution risk, spending levels, or past dilution rather than the headline growth metrics themselves.

Key Terms

orphan drug, fast track, prime designation, investigational new drug, +3 more

7 terms

orphan drug regulatory

"ESP-2001 has potential eligibility for Orphan Drug and Fast Track designations..."

A drug designated for an orphan disease is a medicine developed to treat a rare condition that affects only a small number of people. Regulators often give these drugs special incentives—such as reduced costs, faster review, and temporary exclusive selling rights—to encourage development, which matters to investors because those incentives can make a small market financially viable and reduce competition, much like a temporary patent on a niche product.

fast track regulatory

"ESP-2001 has potential eligibility for Orphan Drug and Fast Track designations..."

A fast track designation is a regulatory label that speeds up the review and communication between a drug developer and regulators for treatments addressing serious illnesses or unmet medical needs. For investors, it matters because it can shorten development time and reduce regulatory delays—like getting a VIP lane at the airport—raising the chance of earlier market access and potential revenue, though it does not guarantee approval.

prime designation regulatory

"as well as PRIME designation from the European Medicines Agency."

A prime designation is a regulatory label given to a drug or medical product that shows strong early evidence of addressing an unmet medical need, granting the developer extra guidance, faster review milestones and increased visibility with regulators. For investors it matters because this status can shorten development time, lower regulatory risk and make a program more attractive to partners or acquirers—think of it as a fast-pass and coaching package that can increase the chances and speed of a product reaching the market.

investigational new drug regulatory

"with the goal of submitting an IND to the U.S. Food and Drug Administration..."

An investigational new drug is a medication that is still being tested in clinical trials to determine if it is safe and effective for treating a specific condition. For investors, it represents a potential breakthrough that could lead to a new treatment and significant financial gains if successful, but also carries risks since it has not yet been approved for widespread use.

ldl-c medical

"low-density lipoprotein cholesterol (LDL-C) goals and remain at heightened risk..."

LDL-C stands for low-density lipoprotein cholesterol, the portion of cholesterol carried in the blood by LDL particles that is commonly linked to buildup of plaque in arteries—think of it like sticky debris that can clog pipes. Investors care because changes in LDL-C are a key measure used by regulators and clinicians to judge the effectiveness of cardiovascular drugs and devices, shape insurance coverage, and influence market demand for treatments that lower heart attack and stroke risk.

hyperuricemia medical

"Hyperuricemia: Bempedoic acid, a component of NEXLIZET and NEXLETOL, may increase blood uric acid..."

Hyperuricemia is a medical condition where uric acid builds up in the blood at higher-than-normal levels, similar to a sink that isn’t draining properly and allows residue to accumulate. It matters to investors because it is the underlying risk factor for gout and kidney stones and a target for drugs and diagnostics; changes in its prevalence, treatment options, or regulatory guidance can affect market size, company revenues, and healthcare spending.

tendon rupture medical

"Tendon Rupture: Bempedoic acid, a component of NEXLIZET and NEXLETOL, is associated with an increased risk..."

A tendon rupture is a complete tear of the tough cord-like tissue that connects a muscle to a bone, like a rope snapping and disconnecting a pulley. For investors, it matters because such injuries can drive demand for medical treatments, surgeries, rehabilitation services, and related drug or device approvals; they can also influence clinical trial outcomes, insurance costs, and revenue forecasts for healthcare companies.

AI-generated analysis. Not financial advice.

– Reports $156 to $160 Million in Preliminary* Full-Year 2025 U.S. Net Product Sales, a 35% to 38% Increase Compared With Full-Year 2024 –

–Total Preliminary* Revenue of $400 to $408 million, a 20% to 23% Increase Compared With Full-Year 2024, and ~55% to 59% Increase Excluding One-Time Milestones –

– Cash and Cash Equivalents of Approximately $168 Million* at Year-End 2025 –

– Q4 Retail Prescription Equivalents Grew 34% Y/Y and 11.3% Q/Q –
        
– Expects Operating Expenses of Between $210 Million and $245 Million for Full-Year 2026 –

– Introduces Vision 2040 Growth Strategy Focused on Global Growth of Cardiometabolic Franchise and Expansion of Pipeline into Rare Hepatic and Renal Diseases –

ANN ARBOR, Mich., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today provides preliminary financial results for the full-year 2025, including U.S. net product sales, cash and cash equivalents and expectations for 2026 operating expenses.

“2025 marked the most successful year in Esperion’s history, driven by exceptional execution across our U.S. commercial strategy, expanded global reach and performance, and significant progress across our pipeline - all while delivering meaningful growth in our cardiovascular franchise and strengthening our financial position. These achievements set the stage for something far bigger: Vision 2040. This bold roadmap reflects our commitment to transform Esperion into a multi-product, sustainable, innovation-driven global pharmaceutical company that not only leads in cardiovascular disease prevention but also addresses a broader spectrum of unmet medical needs,” said Sheldon Koenig, Chief Executive Officer of Esperion.

“By 2040, we envision Esperion as a company with multiple blockbuster products on the market, a robust pipeline of next-generation therapies, and a proven commercial infrastructure that makes us a partner of choice. Our deep expertise in ACLY biology and our relentless focus on patient impact will fuel this evolution. Vision 2040 is more than a strategy—it’s a promise to patients, providers, and shareholders that Esperion will continue to lead with science, scale with purpose, and deliver enduring value for decades to come,” concluded Mr. Koenig.

Introducing Vision 2040

Esperion is pleased to introduce its Vision 2040 that outlines its long-term strategy to evolve into a sustainable, innovation-driven, global pharmaceutical company that is anchored by leadership in cardiometabolic indications including rare and orphan diseases. Esperion’s goal is to leverage the billion-dollar opportunity in its current cardiovascular disease prevention franchise to build a global pharmaceutical company with a growing product portfolio of at least five marketed products and a dynamic discovery engine producing a robust pipeline that addresses a variety of diseases of unmet medical need.

A central component of Vision 2040 is to expand our product portfolio and advance our next-generation development pipeline. The company plans to leverage its proven commercial infrastructure to become a partner-of-choice through acquisition, in-licensing, co-promotion, and revenue-share opportunities. At the same time, Esperion will build on its deep domain expertise in ACLY biology to diversify our therapeutic focus and advance a series of novel product candidates, each with the power to change lives and the potential to become blockbuster products.

Together, these pillars form the foundation for Vision 2040 – a roadmap designed to transform Esperion by uniting scientific leadership, strategic business development, and operational execution. Esperion is positioned to expand its reach, accelerate innovation, and deliver lasting benefits to patients, partners and shareholders.

Advancing the U.S. Commercial Strategy

NEXLETOL^® (bempedoic acid) and NEXLIZET^® (bempedoic acid and ezetimibe) are approved by the U.S. Food and Drug Administration to help prevent heart attacks and cardiovascular procedures in both primary and secondary prevention patients, regardless of statin use. The treatable population represents more than 70 million patients in the U.S. alone. Esperion is currently focusing its commercialization efforts on the statin intolerant or statin resistant market, which represents approximately 30% of the overall market. To address this key market segment, Esperion has ramped up its sales efforts, developed a powerful suite of new promotional materials, created a bold new consumer campaign, enhanced its patient support programs, and continued working with payers to ensure broad patient access.

Importantly, Esperion is undertaking a series of strategic initiatives aimed at reinforcing the long-term protection of the bempedoic acid franchise, including potential extensions of market exclusivity and the introduction of a triple combination product that could provide a level of efficacy with the potential to rival existing injectable and emerging oral therapies.

• Achieved $156 to $160 million in preliminary* full-year 2025 U.S. net product sales, representing a 35% to 38% increase compared with full-year 2024
• Q4 retail prescription equivalents showed 34% Y/Y and 11.3% sequential Q/Q growth.
• Reached settlement agreements with four key ANDA filers, including Dr. Reddy’s Laboratories, restricting generic entry by these parties until April 2040 and leaving no remaining challenges regarding the validity or infringement of U.S Patent No. 7,335,799 in the pending patent litigation. Certain of Esperion’s patents that remain subject to the pending patent litigation are scheduled to expire in March 2036, while others are scheduled to expire in June 2040.
• Significantly strengthened access and reimbursement support for NEXLETOL and NEXLIZET, now exceeding 90% of commercial lives and 90% of Medicare beneficiaries covered, with all national commercial and Medicare payers covering all indications.
• Introduced the “Can’t take a statin? Make NEXLIZET happen!” campaign, which has already increased brand awareness and improved healthcare providers’ perception of NEXLETOL and NEXLIZET among statin-intolerant or resistant patients.
• Enabled the expansion of healthcare providers prescribing NEXLETOL and NEXLIZET from 36,311 to 44,991, a 24% increase in 2025 with strengthened reimbursement and award-winning marketing and educational initiatives.
• Expect bempedoic acid products to be included in the upcoming U.S. Dyslipidemia Guidelines in Q1 2026, which would be a major catalyst to drive adoption and growth of the bempedoic franchise.
• To leverage the strengthened reimbursement, potential expanded timeline to generic entry, and anticipated U.S. guideline inclusion, the Company plans to expand its U.S. commercial efforts through enhanced sales and marketing investments.
• Plans to expand its revenue opportunity in the cardiovascular prevention market with the introduction of two triple combination products. The published literature suggests that the triple combination products can lower LDL-C in excess of 60%. This level of efficacy has the potential to rival existing injectable and emerging oral therapies, offering a valuable oral option for both patients and physicians. The company expanded its partnerships with regulatory experts and others in the field to advance this important work with a goal to complete the clinical requirements and commercialize triple combinations in 2027.
  

Global Expansion

Cardiovascular (CV) disease remains the leading cause of death worldwide, and Esperion continues to make meaningful progress delivering its bempedoic acids products to patients who are unable to achieve their low-density lipoprotein cholesterol (LDL-C) goals and remain at heightened risk of CV disease or a CV event, such as a heart attack. Together with our global partners, we have made significant advancements expanding access to bempedoic acid internationally, strengthening the global footprint of the franchise.

• Daiichi Sankyo Europe, Esperion’s strategic partner across Europe, continued to deliver double digit quarterly growth across key EU markets, and expanded availability of bempedoic acid therapies across 30 countries in the European Union, with more than 600,000 patients treated to date.
  • Bempedoic acid was included as a Class I, Level A recommendation in the 2025 ESC/EAS guidelines.
  • Secured regulatory and reimbursement approval for NILEMDO in France, one of the largest markets in Europe.
  • Announced the development of oral triple combination lipid-lowering tablets, with SANTORINI simulations showing improved LDL-C goal attainment aligned with the 2025 ESC/EAS guidelines.
• Otsuka Pharmaceutical Co., Ltd., Esperion’s strategic partner in Japan, received regulatory approval and favorable National Health Insurance price listing, which resulted in a $90 million total payment to Esperion.
  • Successful commercial launch in late 2025 sets the stage for meaningful growth in 2026.
  • Japan is the third largest global market for cardiovascular prevention, representing significant long-term growth opportunity for NEXLETOL.
• HLS Therapeutics, Esperion’s strategic partner in Canada, received regulatory approval for NILEMDO in late 2025, with approval for NEXLIZET expected in 2026.
• Esperion continues to expect its partner in Israel, Neopharm Israel, to receive regulatory approval to market NEXLETOL and NEXLIZET in the first half of 2026.
• CSL Seqirus, the Company’s partner in Australia and New Zealand, filed a marketing application in Australia for NEXLETOL and NEXLIZET in July 2025, and expects market approval in Q4 2026.

R&D Pipeline

Esperion plans to advance its promising ACLY-focused pipeline, leveraging its established leadership in ACLY biology to pursue new therapeutic opportunities and develop next-generation inhibitors designed to address multiple life-threatening diseases. ACLY is a critical metabolic enzyme positioned at the intersection of nutrient catabolism and cholesterol and fatty acid biosynthesis, making it an attractive target for broad therapeutic intervention.

• Nominated ESP-2001, a highly specific allosteric ATP-citrate lyase inhibitor, as preclinical development candidate for the treatment of primary sclerosing cholangitis (PSC).
• Initiated Investigational New Drug-enabling studies for ESP-2001, with the goal of submitting an IND to the U.S. Food and Drug Administration (FDA) to begin first-in-human clinical studies in 2026.
• With an estimated prevalence of approximately 76,000 diagnosed PSC patients across the U.S. and Europe, and with no approved treatment options, ESP-2001 – a wholly owned asset for which Esperion retains exclusive global development and commercialization rights – represents a potential blockbuster market opportunity of more than $1 billion annually.
• ESP-2001 has potential eligibility for Orphan Drug and Fast Track designations from the U.S. FDA, as well as PRIME designation from the European Medicines Agency.

Financials

Esperion completed a $75.0 million capital raise in 2025, enhancing financial flexibility to support continued commercial expansion and pipeline development.

Esperion introduces its expectations for full-year 2026 operating expenses to be in the range of $210 million to $245 million, including $15 million in non-cash expenses related to stock compensation.  

J.P. Morgan Healthcare Conference Presentation

Esperion will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2025, at 2:15 p.m. PT (5:15 p.m. ET).

The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days.

* The preliminary selected financial results are unaudited, subject to adjustment, and provided as an approximation in advance of the Company’s announcement of complete financial results in March 2026.

INDICATION
NEXLIZET and NEXLETOL are indicated:

• The bempedoic acid component of NEXLIZET and NEXLETOL is indicated to reduce the risk of major adverse cardiovascular events (cardiovascular death, myocardial infarction, stroke, or coronary revascularization) in adults at increased risk for these events who are unable to take recommended statin therapy (including those not taking a statin).
  • NEXLIZET, to reduce LDL-C in adults with hypercholesterolemia, including HeFH.
  • NEXLETOL, in combination with other LDL-C lowering therapies, or alone when concomitant LDL-C lowering therapy is not possible to reduce LDL-C in adults with hypercholesterolemia, including HeFH.
    

IMPORTANT SAFETY INFORMATION
NEXLIZET and NEXLETOL are contraindicated in patients with a prior hypersensitivity to bempedoic acid or ezetimibe or any of the excipients. Serious hypersensitivity reactions including anaphylaxis, angioedema, rash, and urticaria have been reported.

Hyperuricemia: Bempedoic acid, a component of NEXLIZET and NEXLETOL, may increase blood uric acid levels, which may lead to gout. Hyperuricemia may occur early in treatment and persist throughout treatment, returning to baseline following discontinuation of treatment. Assess uric acid levels periodically as clinically indicated. Monitor for signs and symptoms of hyperuricemia, and initiate treatment with urate-lowering drugs as appropriate.

Tendon Rupture: Bempedoic acid, a component of NEXLIZET and NEXLETOL, is associated with an increased risk of tendon rupture or injury. Tendon rupture may occur more frequently in patients over 60 years of age, in those taking corticosteroid or fluoroquinolone drugs, in patients with renal failure, and in patients with previous tendon disorders. Discontinue NEXLIZET or NEXLETOL at the first sign of tendon rupture. Consider alternative therapy in patients who have a history of tendon disorders or tendon rupture.

The most common adverse reactions in the primary hyperlipidemia trials of bempedoic acid, a component of NEXLIZET and NEXLETOL, in ≥2% of patients and greater than placebo were upper respiratory tract infection, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia, and elevated liver enzymes.

Adverse reactions reported in ≥2% of patients treated with ezetimibe (a component of NEXLIZET) and at an incidence greater than placebo in clinical trials were upper respiratory tract infection, diarrhea, arthralgia, sinusitis, pain in extremity, fatigue, and influenza.

In the primary hyperlipidemia trials of NEXLIZET, the most commonly reported adverse reactions (incidence ≥3% and greater than placebo) observed with NEXLIZET, but not observed in clinical trials of bempedoic acid or ezetimibe, were urinary tract infection, nasopharyngitis, and constipation.

The most common adverse reactions in the cardiovascular outcomes trial for bempedoic acid, a component of NEXLIZET and NEXLETOL, at an incidence of ≥2% and 0.5% greater than placebo were hyperuricemia, renal impairment, anemia, elevated liver enzymes, muscle spasms, gout, and cholelithiasis.

Discontinue NEXLIZET or NEXLETOL when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus. Because of the potential for serious adverse reactions in a breast-fed infant, breastfeeding is not recommended during treatment with NEXLIZET or NEXLETOL.

Report pregnancies to Esperion Therapeutics, Inc. Adverse Event reporting line at 1-833-377-7633.

Please see full Prescribing Information for NEXLIZET and NEXLETOL.

About Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative cardiometabolic and rare/orphan disease therapies. The Company leverages deep domain expertise in ACLY biology to develop and commercialize transformative medicines for patients worldwide. Esperion currently markets two oral, once-daily, non-statin therapies for patients struggling to maintain their low-density lipoprotein cholesterol (LDL-C) levels and are at risk of cardiovascular disease.

With a broad U.S. commercial infrastructure and global approvals across more than 40 countries, Esperion is well positioned to serve as a partner-of-choice for global innovators seeking U.S. market access through acquisition, in-license, co-promotion and revenue share opportunities. In tandem, the Company is advancing its leadership in ACLY biology to build a diversified pipeline of novel product candidates, including treatments for Primary Sclerosing Cholangitis and renal diseases. For more information, visit esperion.com and follow Esperion on LinkedIn and X.

Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization and business development plans, current and planned operational expenses, expected profitability, future operations, commercial products, clinical development, including the timing, designs and plans for the CLEAR Outcomes study and its results, plans for potential future product candidates, financial condition and outlook, including expected cash runway and profitability, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Esperion’s actual results to differ significantly from those projected, including, without limitation, the net sales, profitability, and growth of Esperion’s commercial products, clinical activities and results, supply chain, commercial development and launch plans, business development, the outcomes and anticipated benefits of legal proceedings and settlements, and the risks detailed in Esperion’s filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Esperion disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903

Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438

FAQ

What were Esperion's preliminary full‑year 2025 U.S. net product sales (ESPR)?

Esperion reported preliminary U.S. net product sales of $156–$160 million for full‑year 2025, a 35%–38% increase versus 2024.

How much cash did Esperion (ESPR) report at year‑end 2025 and what does it imply?

Esperion reported approximately $168 million in cash and cash equivalents at year‑end 2025; management expects 2026 operating expenses of $210–$245 million.

What patent or exclusivity developments did Esperion announce that affect ESPR shareholders?

Esperion reached settlement agreements with four ANDA filers restricting generic entry by those parties until April 2040 and reported patent expirations in 2036 and June 2040 for other patents.

What growth strategy did Esperion unveil on Jan 11, 2026 for ESPR?

Esperion introduced Vision 2040, targeting a multi‑product global cardiometabolic franchise, expansion via M&A/in‑licensing, and advancement of ACLY‑focused pipeline assets.

When does Esperion expect to commercialize its oral triple combination lipid therapies and what is the expected efficacy?

Esperion aims to complete clinical requirements and commercialize triple combination products in 2027; published literature suggests LDL‑C reductions in excess of 60% for similar triple combinations.

What near‑term clinical development did Esperion announce for ESP‑2001 (ESPR)?

Esperion nominated ESP‑2001 as a preclinical candidate for primary sclerosing cholangitis (PSC), initiated IND‑enabling studies, and expects to submit an IND to the FDA to start first‑in‑human studies in 2026.